SquamousCellCarcinomaofSkin near Englewood Cliffs, NJ

Biography: Divaya Bhutani, MD, is a world-leading expert in multiple myeloma therapies and treatment strategies whose work in this field has been extensively published. As a hematologist and oncologist at NewYork-Presbyterian Lawrence Hospital, he specializes in cancer care, blood disorders, and benign hematology. He also serves as an assistant professor of medicine at Columbia University Irving Medical Center. As an expert in myeloma, Dr. Bhutani is a member of several professional organizations including the American Society of Clinical Oncology, the American Society of Hematology, and the American Society for Blood and Marrow Transplantation. A well-respected and accomplished researcher, Dr. Bhutani has presented his work at at annual medical meetings of the American Society of Hematology and has been featured in medical journals, including Pharmacology & Therapeutics and Journal of Clinical Oncology. Dr. Divaya Bhutani graduated from Govt. Medical College, Patiala in India. He did his Internal medicine residency at Mount Sinai School of Medicine, Bronx, NY and fellowship in Hematology and Oncology at Wayne State University and Karmanos Cancer Institute, Detroit. His prior experience includes work as an Attending Physician at Myeloma Institute of Research and Therapy at University of Arkansas for Medical Sciences, Little Rock, AR and Karmanos Cancer Institute, Wayne State University, Detroit. MI.

Care Philosophy: We are committed to delivering the best care and an exceptional patient experience We are devoted to providing services that are patient centered and compassionate and care for you as a person nbsp;

Biography: Myron M. Studner Professor of Cancer Research and Professor of Medicine and Epidemiology at Columbia University, Associate Director for Population Science, Leader of the Prevention, Control, and Disparities Program for the Herbert Irving Comprehensive Cancer Center at Columbia, and Co-Director of the Cancer Prevention Center of New York Presbyterian Hospital Dr. Neugut is a medical oncologist with a particular interest in gastroIntestinal tract cancers, especially of colorectal and gasteric cancers. Under the auspices of Columbia's MD/PhD program, he received his MD and a PhD in Pathobiology in 1977. He did his training in Internal Medicine at the Albert Einstein College of Medicine and fellowship in Medical Oncology at Memorial Sloan-Kettering Cancer Center. He returned to Columbia University as an Andrew Mellon Fellow in Epidemiology and Medicine to obtain an MPH in Epidemiology in 1983. Dr. Neugut then joined the faculty at Columbia University with appointments in Medicine and Epidemiology. As both a practicing medical oncologist and cancer epidemiologist, Dr. Alfred Neugut's major interests have been on GI tract cancers, notably the epidemiology of colorectal adenomas and cancer, as well as colonoscopic screening. He serves as co-principal investigator of the Long Island Breast Cancer Study Project, a large multi-center effort to explore environmental causes of breast cancer on Long Island. Most recently, his efforts have focused on more clinical topics, such as the epidemiology of second malignancies and the use of chemotherapy and radiation therapy among elderly cancer patients. Dr. Neugut focuses a great deal on racial disparities in incidence and survival from cancer and, in particular, variations across subgroups of people of African descent. He leads two large training grants in cancer-related population sciences that together fund 15 pre and postdoctoral trainees in cancer epidemiology, biostatistics, and environmental health sciences, and serves as a mentor to a number of junior faculty.

Biography: Dr. Fojo received his MD and PhD from the University of Miami and completed internal medicine training at Washington University School of Medicine / Barnes Hospital. He joined the National Cancer Institute in 1982 as a Clinical Associate in the Medicine Branch and after training with Drs. Ira Pastan and Michael Gottesman, became a Principal Investigator in the Medicine Branch of the National Cancer Institute. As a Principal Investigator he went on to establish a highly successful translational clinical program that began by exploring agents to reverse drug resistance, continued with work on the optimal use of Taxol®, and the development of novel microtubule-targeting agents and has focused on the development of therapies for endocrine and neuroendocrine cancers. Dr. Fojo has expertise in the management of patients with adrenocortical cancer, malignant pheochromocytoma and other neuroendocrine malignancies, and thyroid cancer. These cancers also comprise areas of very active basic science interest given their unique properties and the possibilities to target such cancers more precisely. The ultimate goal is to develop novel therapies for these often very refractory cancers so that there will be additional options available for treatment for patients with these cancers. Ongoing laboratory efforts are focused on developing such novel therapies to treat patients with adrenal cancer, pheochromocytoma and a spectrum of neuroendocrine tumors. In the laboratory Dr. Fojo has also worked to understand the molecular basis of drug resistance, and was involved in the original work relating to several ABC transporters. Additionally, his laboratory originally identified rearrangements involving the MDR-1 gene as a novel mechanism of drug resistance in several cancers, a molecular event recently demonstrated as very important in ovarian cancer. He has also been very involved in research on microtubule-targeting agents, helping to establish as a novel paradigm the interference with microtubule trafficking, rather than mitosis, for the mechanism of action for these important drugs. In addition to his clinical expertise Dr. Fojo has been very interested in the design, conduct and interpretation of oncology clinical trials and in collaboration with Wilfred Stein, PhD and Susan Bates, MD has helped to pioneer a novel method of analysis that dissects rates of tumor growth and regression as concurrent events. Related to this he has also written extensively about the cost of cancer therapeutics, the magnitude of the problem and how this might be addressed. Dr. Fojo served as Program Director for the Medical Oncology Fellowship Program at the National Cancer Institute, the largest fellowship program in the NIH and one of the largest medical oncology programs in the United States. Over the years Dr. Fojo has helped to train more than 350 medical oncologists.